Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.

PURPOSE To compare breast cancer prognosis in BRCA1 and BRCA2 mutation carriers with that in patients with sporadic disease. PATIENTS AND METHODS An international population-based cohort study was conducted in Canada, the United States, and Australia of 3,220 women with incident breast cancer diagnosed between 1995 and 2000 and observed prospectively. Ninety-three had BRCA1 mutations; 71, BRCA2 mutations; one, both mutations; 1,550, sporadic breast cancer; and 1,505, familial breast cancer (without known BRCA1 or BRCA2 mutation). Distant recurrence and death were analyzed. RESULTS Mean age at diagnosis was 45.3 years; mean follow-up was 7.9 years. Risks of distant recurrence and death did not differ significantly between BRCA1 mutation carriers and those with sporadic disease in univariable and multivariable analyses. Risk of distant recurrence was higher for BRCA2 mutation carriers compared with those with sporadic disease in univariable analysis (hazard ratio [HR], 1.63; 95% CI, 1.02 to 2.60; P = .04). Risk of death was also higher in BRCA2 carriers in univariable analysis (HR, 1.81; 95% CI, 1.15 to 2.86; P = .01). After adjustment for age, tumor stage and grade, nodal status, hormone receptors, and year of diagnosis, no differences were observed for distant recurrence (HR, 1.00; 95% CI, 0.62 to 1.61; P = 1.00) or death (HR, 1.12; 95% CI, 0.70 to 1.79; P = .64). CONCLUSION Outcomes of BRCA1 mutation carriers were similar to those of patients with sporadic breast cancer. Worse outcomes in BRCA2 mutation carriers in univariable analysis seem to reflect the presence of more adverse tumor characteristics in these carriers. Similar outcomes were identified in BRCA2 carriers and those with sporadic disease in multivariable analyses.

[1]  A. Howell,et al.  Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy , 2002, International journal of cancer.

[2]  G M Lenoir,et al.  Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.

[3]  P Borgen,et al.  Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. , 1999, Journal of the National Cancer Institute.

[4]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Andrulis,et al.  Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Klijn,et al.  Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. , 2007, European journal of cancer.

[7]  K. Phillips.  Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Andrulis,et al.  HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry , 2002, Cancer.

[9]  D. Evans,et al.  Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients , 2008, Clinical Cancer Research.

[10]  L. Bégin,et al.  Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  I. Andrulis,et al.  Frequency of p 53 Mutations in Breast Carcinomas From Ashkenazi Jewish Carriers of BRCA 1 Mutations , 1999 .

[12]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Cossu,et al.  Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia , 2009, BMC Cancer.

[14]  N. Voirin,et al.  Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review , 2006, Breast Cancer Research and Treatment.

[15]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[16]  J. Benítez,et al.  The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications , 2005, Modern Pathology.

[17]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[18]  A. Whittemore,et al.  Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.

[19]  A. Whittemore,et al.  Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry , 2009, Breast Cancer Research and Treatment.

[20]  Ofra Barnett-Griness,et al.  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.

[21]  W. Rubinstein.  Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics , 2007, Familial Cancer.

[22]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[23]  John L Hopper,et al.  Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. , 2003, Journal of the National Cancer Institute.

[24]  J. Klijn,et al.  Survival and prognostic factors in BRCA1-associated breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Whittemore,et al.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research , 2009, Breast Cancer Research and Treatment.

[26]  L. Bégin,et al.  Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Bégin,et al.  Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Whittemore,et al.  BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays , 2007, The American journal of surgical pathology.

[31]  A. Musolino,et al.  BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. , 2007, Breast.

[32]  P. Goodwin,et al.  Prognosis of BRCA-associated breast cancer: a summary of evidence , 2009, Breast Cancer Research and Treatment.

[33]  Å. Borg,et al.  Prognosis and clinical presentation of BRCA2-associated breast cancer. , 2000, European journal of cancer.

[34]  U. Chetty,et al.  Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12–21 , 1994, The British journal of surgery.

[35]  A. Vincent-Salomon,et al.  Familial invasive breast cancers: worse outcome related to BRCA1 mutations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Chenevix-Trench,et al.  Germ‐line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen‐responsive proteins and the predominance of progesterone receptor A , 2004, Genes, chromosomes & cancer.

[37]  N. Boyd,et al.  Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. , 2002, Annals of epidemiology.

[38]  Caroline Seynaeve,et al.  Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients , 2008, Breast Cancer Research and Treatment.

[39]  B. Ponder,et al.  Effect of germ-line genetic variation on breast cancer survival in a population-based study. , 2002, Cancer research.

[40]  C. Lewis,et al.  Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  I. Andrulis,et al.  Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. , 1999, Journal of the National Cancer Institute.

[42]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.